Brainstorm cell therapeutics inc. (BCLI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Operating expenses:
Research and development, net

19,696

17,204

14,878

12,845

10,772

8,293

2,866

2,059

1,013

977

2,867

2,489

2,205

2,250

2,753

3,466

4,690

4,949

5,766

5,835

5,337

4,772

3,978

3,210

3,075

2,917

2,352

2,280

1,923

1,770

2,143

1,587

1,788

1,689

1,403

879

0

0

0

General and administrative

6,685

5,797

5,895

5,609

5,912

5,770

5,522

5,489

4,523

4,022

3,020

2,644

2,836

2,833

3,077

3,297

3,453

3,587

4,039

3,829

3,258

2,649

2,178

1,592

1,918

2,126

1,924

2,092

1,797

1,748

1,952

2,076

2,457

2,205

1,915

1,083

0

0

0

Financial expenses (income), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

317

151

13

57

0

0

0

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

264

264

132

132

0

0

0

0

0

Operating loss

-26,381

-23,001

-20,773

-18,454

-16,684

-14,063

-8,388

-7,548

-5,536

-4,999

-5,887

-5,133

-5,041

-5,083

-5,830

-6,763

-8,143

-8,536

-8,725

-8,584

-7,515

-7,421

-7,071

-5,722

-5,928

-4,899

-4,241

-4,310

-3,639

-3,425

-7,863

-7,407

-5,486

-3,913

1,783

0

0

0

-

Total operating costs and expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,993

5,043

4,276

4,372

3,720

3,518

4,095

3,663

4,245

3,894

3,318

1,962

0

0

0

Financial expenses (income), net

-41

252

171

32

-7

-115

-99

-32

-71

-47

-35

-78

-64

-101

-88

-24

-101

-48

29

-12

776

1,825

1,596

1,610

935

-144

-1

-10

0

-

0

0

-

-

-

-

-

-

-

Total loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Taxes on income (Note 12)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

19

18

1

5

15

15

9

5

-29

-29

0

0

0

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,640

-3,430

-7,878

-7,422

-5,495

-3,918

1,812

3,120

0

0

0

Net loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Net loss

-26,340

-23,253

-20,944

-18,486

-16,677

-13,948

-8,289

-7,516

-5,465

-4,952

-5,852

-5,055

-4,977

-4,982

-5,742

-6,739

-8,042

-8,488

-9,834

-9,652

-9,371

-9,246

-7,733

-6,394

-5,928

-4,899

-4,260

-4,328

-3,640

-3,430

-6,468

-6,012

-4,085

-3,918

402

1,710

0

0

0

Basic and diluted net loss per share from continuing operations

-0.32

-

-0.25

-0.23

-0.24

-

-0.15

-0.16

-0.12

0.03

-0.13

-0.06

-0.10

-0.03

-0.09

-0.05

-0.10

-0.08

-0.14

-0.12

-0.12

-0.54

-0.16

-0.16

0.18

0.34

0.10

0.01

0.01

0.05

-0.01

-0.01

-0.01

-0.04

-0.01

0.01

0.01

0.01

0.01

Weighted average number of shares outstanding used in computing basic and diluted net loss per share

28,423

22,749

22,254

21,703

20,917

20,746

20,691

19,505

19,047

18,898

18,783

18,738

18,688

18,688

18,656

18,654

18,653

18,562

18,480

18,450

18,128

15,322

15,158

12,416

11,753

-271,495

10,948

152,546

150,953

150,308

145,407

128,078

126,591

125,724

124,596

121,253

108,895

91,606

88,609